Bayesian Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Bayesian Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,277	Closed	-$189K	–	158
2025 Q4	$189K	Buy	+20,277	New	+$169K	0.43%	94
2025 Q3	–	Sell	-28,100	Closed	-$183K	–	596
2025 Q2	$183K	Buy	28,100 +10,100	+56%	+$69.5K	0.03%	466
2025 Q1	$143K	Buy	+18,000	New	+$194K	0.02%	521
2024 Q4	–	Sell	-18,874	Closed	-$263K	–	751
2024 Q3	$263K	Buy	+18,874	New	+$269K	0.03%	505
2024 Q2	–	Sell	-13,374	Closed	-$221K	–	821
2024 Q1	$221K	Buy	+13,374	New	+$200K	0.02%	637
2023 Q3	–	Sell	-15,834	Closed	-$189K	–	757
2023 Q2	$189K	Buy	+15,834	New	+$207K	0.02%	645
2022 Q4	–	Sell	-13,508	Closed	-$271K	–	832
2022 Q3	$271K	Buy	+13,508	New	+$287K	0.05%	442

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Bayesian Capital Management's DAWN Position: Q1 2026 in Review

Bayesian Capital Management sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 20,277 shares — an estimated $189K sold.

Bayesian Capital Management first reported a position in DAWN in Q3 2022 and held it in 7 quarters. The position peaked at $271K in Q3 2022. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Bayesian Capital Management reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
Bayesian Capital Management sold 20,277 Day One Biopharmaceuticals shares in Q1 2026, an estimated $189K.
Bayesian Capital Management first reported a position in Day One Biopharmaceuticals in Q3 2022 and held it in 7 quarters.
Bayesian Capital Management's Day One Biopharmaceuticals position peaked at $271K in Q3 2022.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Bayesian Capital Management's 13F filing for Q1 2026, filed 15 May 2026.